UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2025

Commission File Number: **001-42128**

Telix Pharmaceuticals Limited

(Translation of registrant's name into English)

55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On January 13, 2025, Telix Pharmaceuticals Limited (the "Company") filed with the Australian Securities Exchange (the "ASX") an announcement captioned "Telix Exceeds FY24 Guidance with US$142M Q4 Revenue," a copy of which is attached to this Form 6-K as Exhibit 99.1.

On January 13, 2025, the Company filed a presentation with the ASX captioned "Telix JP Morgan Healthcare Conference 2025 Presentation," a copy of which is attached to this Form 6-K as Exhibit 99.2.

99.1	Press release – January 13, 2025.
99.2	Presentation – January 13, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Telix Pharmaceuticals Limited

Date: January 13, 2025

By: /s/ Genevieve Ryan

Name: Genevieve Ryan
Title: Company Secretary

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 13 January 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).

Sustained revenue growth

- Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million)[1], represents an increase of 46% over the prior year corresponding quarter (Q4 2023: US$97 million or AU$148 million) and a quarter-over-quarter increase of 5% (Q3 2024: US$135 million or AU$201 million).
- Telix's revenue is currently generated predominantly from sales of Illuccix®, its diagnostic radiopharmaceutical for prostate cancer PET[2] imaging.

Full year guidance exceeded

- Total FY2024 unaudited revenue is approximately US$517 million (AU$783 million) exceeding previously stated guidance of US$490 million to US$510 million (AU$745 million to AU$776 million), representing a 55% increase over FY2023.
- FY2024 investment into research and development (R&D) remains in line with guidance, funded by earnings generated from product sales.
- The Company intends to provide FY2025 guidance when it reports audited FY2024 annual results on 20 February 2025.

Q4 2024 business update

Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer, Telix, said, "This has been another great quarter of commercial performance. Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet and the Nasdaq listing were major corporate milestones. The acquisition of FAP-targeting assets is a major addition to our superb product pipeline. We are well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets into pivotal trials. 2025 is shaping up to be transformative year for Telix."

Therapeutics Business

- **Prostate cancer therapy candidate, TLX591 (^{177}Lu-rosapatamab):** During Q4 2024 Telix progressed ProstACT GLOBAL, the registrational clinical trial for Telix's lead clinical therapeutic asset with first interim read out expected in H1 2025.

- **Kidney cancer therapy candidate, TLX250 (^{177}Lu-girentuximab):** The Company was granted a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, to discuss a proposed Telix-sponsored pivotal trial of TLX250.

[1] Total revenue for Q4 2024 and year-to-date (FY2024) is provided on an unaudited basis. Conversion to AU$ is at an average exchange rate realized during Q4 2024 of AU$1 = US$0.651

- **Glioblastoma therapy candidate, TLX101 (^{131}I-iodofalan, or ^{131}I-IPA):** During Q4 2024, the Company held a pre-IND meeting with the FDA to discuss the design of a pivotal trial for TLX101. Based on positive feedback from the meeting, Telix will move forward with an IND submission in H1 2025.

- **Fibroblast Activation Protein (FAP) targeting therapy candidate, TLX400:** Telix entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated assets targeting FAP. FAP is one of the most promising pan-cancer targets, with an initial focus on bladder cancer rounding out Telix's leading urology theranostics franchise.

- **Proprietary engineered antibody platform and pipeline:** Today, Telix announced it has entered into a transaction with ImaginAb Inc. to acquire a groundbreaking platform technology and drug discovery capability, along with a pipeline of next-generation biologic-based therapeutic candidates with significant potential to deliver future innovation in radiopharmaceuticals[3].

Precision Medicine Business

- **Kidney cancer imaging, TLX250-CDx (Zircaix®[4], ^{89}Zr-girentuximab):** Telix submitted a Biologics License Application (BLA) for its renal cancer imaging candidate on 27 December 2024 and continues to target a U.S. commercial launch in H2 2025[5].

- **Brain cancer imaging, TLX101-CDx, (Pixclara®[4], ^{18}F-floretyrosine or ^{18}F-FET):** The FDA formally accepted Telix's New Drug Application (NDA), granted a Priority Review and provided a PDUFA[6] goal date of 26 April 2025.

- **Illuccix® global regulatory submissions:** The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, or BfArM) is expected to provide its decision on the Company's EU marketing authorization application on 15 January 2025. In the United Kingdom (UK), the Company has responded to all queries with no substantive issues raised. The UK regulator (the Medicines and Healthcare Products Regulatory Agency - MHRA) is experiencing significant administrative delays but an approval decision is expected this month. The Brazilian Health Regulatory Agency (ANVISA) is expected to provide a decision imminently after protracted administrative delays also unrelated to Telix's marketing authorization application.

- **MedTech partnership with Subtle Medical:** Telix has concluded a partnership with California-based Subtle Medical, Inc. for artificial intelligence (AI)-powered PET imaging with Illuccix[7]. This technology enhances scanning workflow, increasing scanner throughput and capacity.

- **Scintimun®:** Today, Telix announced that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (^{99m}Tc-besilesomab, also known as TLX66-CDx)[8]. Scintimun is approved in 33 countries to image infection (osteomyelitis), with significant clinical indication expansion and theranostic potential.

[2] Positron emission tomography.

[3] Telix ASX disclosure 13 January 2025.

[4] Brand name subject to final regulatory approval.

[5] The 27 December 2024 BLA submission to the FDA is intended to remediate a filing issue with the initial BLA submission from June 2024. See Telix ASX disclosures 31 July 2024 and 30 December 2024.

[6] Prescription Drug User Fee Act.

[7] Telix media release 30 October 2024.

Telix Manufacturing Solutions (TMS)

- **RLS (USA) Inc acquisition:** During Q4 2024, Telix progressed integration planning and expects to close the transaction in the first quarter of 2025[9].

- **Brussels South production facility buildout:** Telix completed the installation of two new cyclotrons at its facility in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses on-site from 2025[10]. Formal Good Manufacturing Practice (GMP) accreditation for the facility is expected imminently.

Corporate milestones

- On 14 November 2024, Telix American Depository Shares (ADSs) commenced trading on the Nasdaq Global Select Market (Nasdaq) under the symbol 'TLX'[11]. Telix continues to maintain its primary listing on the Australian Securities Exchange (ASX).

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), Canada, and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Telix's lead imaging product, gallium-68 (^{68}Ga) gozetotide injection (also known as ^{68}Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA[12], the Australian Therapeutic Goods Administration (TGA)[13], and Health Canada[14]. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

[8] Telix media release 13 January 2025.
[9] Telix ASX disclosure 23 September 2024.
[10] Telix media release 19 December 2024.
[11] Telix ASX disclosure 14 November 2024.
[12] Telix ASX disclosure 20 December 2021.
[13] Telix ASX disclosure 2 November 2021.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated benefits of Telix's acquisitions; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

[14] Telix ASX disclosure 14 October 2022.

Telix

Defining the Future of Radiopharma

JP Morgan 43rd Annual Healthcare Conference, 12-16 January 2025

NASDAQ: TLX | ASX: TLX

Disclaimer

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the A Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, includir result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation c completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigatic performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expres uncertainties and other factors that may cause Telix's actual results, levels of activity, performance or achievements to diff achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's g risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, pr research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's al for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's fir industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's ac from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you sho

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to mar of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, proj the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Telix's lead imaging product, gallium-68 (^{68}Ga) gozetotide injection (also known as ^{68}Ga PSMA-11 and marketed under the b Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix produ

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the

Telix

Company Overview

Theranostics are the future of oncology

A powerful way to tackle cancer

"See It, Treat It"

- Highly-targeted
- Patient-centric
- Personalized

TLX101 Therapy: Patient with glioblastoma, TLX101-CDx PET imaging demonstrating response at 4 months[1]



Baseline T=0
TLX101-CDx
(Pixclara®[3],
[^{18}F] FET) PET[4]

Treatment with TLX101
T=9 weeks
T= 13 weeks
Overlay post therapy
SPECT[5]

Follow up
T=19 weeks
TLX101-CDx
PET

TLX400 t
demonstrati

Before



Baseline T=0
TLX400-CDx
FAP-targeted PE

Telix

1. TLX101 Compassionate Use program. Case study presented at EANM October 2024. Credit N. Tolboom, UMC Utrecht.
2. ^{177}Lu-based, FAP-targeted therapeutic candidate.
3. Brand name subject to final regulatory approval.
4. Positron emission tomography.
5. Single photon emission computed tomogr

Telix: A unique company

We are leading the theranostic medicine modality

The **only** pure-play radiopharmaceutical company with:

Strong commercial record
FY2024 revenue: US$517M – 55% increase YOY[1]

Deep theranostic pipeline – multiple near-term catalysts plus next-generation assets



Telix

Patient representative scans – individual results may vary.

1. FY2024 revenues are unaudited, preliminary and based on management's estimate as of the date of this presentation and a
   Refer to ASX and SEC announcement in respect of Telix's Q4 2024 revenue and business update dated 13 January 2025 f

Commercial performance

Full year guidance - beat

Total revenue

US$M



1. FY2024 revenues are unaudited, preliminary and based on management's estimate as of the date of this presentation and a ASX and SEC announcement in respect of Telix's Q4 2024 revenue and business update dated 13 January 2025 for further

2025 Roadmap

Clear strategy, multiple near-term value drivers

Commercial portfolio and geographic expansion

Preparing for multi-product launches in 2025

U.S.: Zircaix®[1] BLA submitted; PDUFA dates for Gozellix®[2] and Pixclara®[3]

Global expansion of Illuccix®



Late-stage therapeutic pipeline

Focus on urology, neuro-oncology and musculoskeletal oncology, **targeting three assets in pivotal trials in 2025**

Advancing "nex radiopharm

Harnessing th **alpha emitti** and further **in-house plat**

Telix

1. Zircaix®: TLX250-CDx for kidney cancer imaging, brand name subject to final regulatory approval.
2. Gozellix®: TLX007-CDx for prostate cancer imaging, brand name subject to final regulatory approval.
3. Pixclara®: TLX101-CDx for glioma imaging, brand name subject to final regulatory approval.

The immediate opportunity

High unmet medical need, significant value creation



Our precision medicine portfolio provides near-term revenue op
validates the clinical and commercial potential of our therapeut

Telix

Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.
1. Management estimate for 2025 based on latest incidence and pricing models.


Therapeutics
Platform

Therapeutics strategy

Multiple near-term catalysts and next-generation assets

	Prostate cancer	RCC, other CAIX[1]-expressing t
Progress multiple late-stage therapeutic assets to pivotal trials	β **TLX591** Potential first radiolabelled antibody (rADC)[2] in 1L/2L mCRPC[3]	β **TLX250** Potential first-in-c radiopharmaceut (rADC) in metast ccRCC[4]
	β **TLX090** Novel osteoblastic bone metastases palliation	
Advance next-generation radiopharma platform	α **TLX592** Follow-on opportunity with Actinium-225 labelled antibody. Alternate clinical settings with unmet need	α **TLX252** Pan-cancer targe enables expansic other CAIX-expre tumors with alpha emitter

Telix

1. Carbonic anhydrase IX.
2. Radio antibody-drug conjugate.
3. Metastatic castrate resistant prostate cancer.
4. Clear cell renal cell carcinoma.

Late-stage pipeline

Clinically-validated programs, targeting three assets in piv

	Targeting agent	Isotope	Phase 1	Phase 2	Phas
Prostate PSMA[1]	Antibody	^{177}Lu	TLX591 (^{177}Lu rosopatamab tetraxetan)		
Kidney + other CAIX	Antibody	^{177}Lu	TLX250 (^{177}Lu-girentuximab)		
Brain LAT[2]	Small molecule	^{131}I	TLX101 (^{131}I-IPA)		
Musculo-skeletal	Antibody	^{90}Y	TLX66 (^{90}Y-besilesomab), CD66[3] targeting agent for bor marrow conditioning for hematological diseases		
	Small molecule	^{153}Sm	TLX090 (^{153}Sm-DOTMP), bone-seeking agent for bone metastases and pain palliation		

Telix

1. Prostate-specific membrane antigen.
2. L-type amino acid transporter.
3. Cluster of differentiation 66.
4. Investigational new drug (application).

Early-stage pipeline

The “next generation” of products

	Targeting agent	Isotope	R&D	Pre-cli
Prostate PSMA	Antibody	^{225}Ac (alpha)	TLX592 (^{225}Ac-RADmAb®)	
Kidney + other CAIX	Antibody	^{225}Ac (alpha)	TLX252 (^{225}Ac-girentuximab)	
Brain LAT	Small molecule	^{211}At (alpha)	TLX102 (^{211}At-APA)	
Sarcoma PDGFRα[1]	Antibody	Undisclosed	TLX300 (-olaratumab)	
Bladder FAP[2]	Small molecule	Undisclosed	TLX400 (New in-license)	

Telix

1. Platelet derived growth factor receptor alpha.
2. Fibroblast activation protein.

TLX591: A highly differentiated approach

Potential to overcome limitations of small molecule approa

ProstACT™

SURVIVAL	Promising overall survival demonstrated in early studies, median OS 42.3 months[1]
DOSING	Simple 2-dose regimen Lower cumulative radiation exposure (152 mCi v 1200 mCi)
QoL[2]	Limited off target side effects: renal toxicity, dry mouth, dry eye, ganglia irritation. Predictable hematological response



Ke

ProstACT GLO
Interim readout

Telix

1. Tagawa, et al. *Cancer.* 2019 (Open label, single-arm Phase 1/2 clinical trial in 17 patients with advanced mCRPC).
2. Quality of life.
3. ProstACT SELECT data on file.

TLX250: Targeting ccRCC, pan-cancer pot

Positioned to be first CAIX-targeting rADC to market

TLX250-CDx detection of CAIX expressing tumors



Patient representative scans - individual results may vary.

1. Computed tomography.
2. Pastorekova S and Gillies RJ. *Cancer Metastasis Rev*. 2019.
3. Shuch et al. *Lancet Oncology*. 2024.
4. Stillbroer et al. *European Urol*
5. Muselaers et al. *European Ur*
6. Alves WEFM et al. *BMC Canc*

TLX101: Impacting glioblastoma

A compelling direction for an unmet medical need

TLX101 scan showing glioblastoma uptake[1]



Overlay post therapy SPECT/MRI[2]

- **Patient need**: Glioblastoma currently h
  survival of 12-15 months[3], 5-year survi
- TLX101 granted orphan drug designati
  glioma
- **Companion diagnostic:** Pixclara[4] (TL
  granted Priority Review with a PDUFA[6]
- **Clinical outcomes**: IPAX-1 demonstra
  survival of 23 months from initial diagn

Two key near-te

IPAX-2: Phase 1 study in front-line setting

In progress, positive engagement with FDA on pivotal trial design, planned commencement 2025

Telix

Patient representative scan - individual results may vary.

1. Credit: UMC Utrecht Compassionate Use Program.
2. Magnetic resonance imaging.
3. Ostrom et al. *Neuro Oncol.* 2018.
4. Brand name subject to final regulatory approval.
5. New drug application.

TLX090: Next generation for metastatic ca

Pain management and palliative treatment of osteoblastic

SPECT/CT scan of metastatic prostate cancer patient showing targeted uptake of TLX090



- **Patient need:** Relief from pain due to bon
  cost-effective solutions. Current standard
  compliance issues, and offering low quality
- Most prostate cancer patients and 20% of
  lesions, with considerable pain[1]
- **Benefits**: Single dose of TLX090 potential
  and quality of life. Repeat dosing potential
- **Clinical outcomes**: Phase 1 trial demons
  tumors, favorable safety profile and efficac

Two key near-t

Dec 2024 Type B Pre-IND Meeting

Received clear guidance on planned study design and pathway to pivotal trial

Telix

Patient representative scans - individual results may vary.

1. Huang, J., et al., (2020). Incidence Of Patients with Bone Metastases At Diagnosis Of Solid Tumors In Adults: A Large Population-Based Study. Doi: 10.21037/atm.2020.03.55

TLX400: Fibroblast activation protein (FAI

Next-generation asset, pan-cancer potential

FAP therapy (TLX400) in RAI-R[1]-thyroid cancer[2]



- **Fibroblast activation p** the most potential in nu of epithelial cancers[3]
- **Next-generation asset** alpha and beta therapy
- **Demonstrated safety a** clinical and clinical valid
- **Developed by** renowne and team
- **Bolsters Telix pipeline** complementing our CAI
- **Initial development pr** out existing urology fran

Telix

Patient representative scans - individual results may vary.

1. Radioactive iodine-refractory thyroid cancer.
2. Adapted from Sanjana Ballal, SNMMI Presentation 2023.
3. Rettig et al. *Proc Natl Acad Sci USA*

Precision Medicine



Precision medicine strategy

Expanding Telix's industry-leading precision medicine fra

	New product launches[1]	Global expansio and patient rea
Multiple commercial products	Preparation for U.S. launches in 2025 for • Gozellix® (prostate) • Pixclara® (GBM[2]) • Zircaix® (renal)	• Illuccix® approvals expected in EU, U Brazil in 2025 • Illuccix Phase 3 br studies - China an Japan
Clinical leadership in precision medicine	• Label expansion and multi-product lifecycle development for PSMA imaging • Label expansion studies for kidney and brain[2]	• Regulatory filings support global roll of Gozellix, Pixcla and Zircaix • Supporting multipl third-party clinical trials globally

Telix

Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.

1. Subject to regulatory approval.
2. Glioblastoma.
3. Artificial intelligence.

Global product expansion

Transition to a global, multi-product commercial product p

PSMA Prostate

- Gozellix: follow-on PSMA product, PDUFA goal date 24 March 2025
- Illuccix: EU decision date mid-January, UK and Brazil decisions expected H1 2025
- China: Illuccix Phase 3 bridging study complete

illuccix®
(kit for the preparation of gallium Ga 68 gozetotide Injection)

Gozellix™
kit for the preparation of gallium Ga 68 gozetotide injection

CAIX Kidney

- Zircaix BLA filed with the FDA December 2024[1]
- Expanded access program at >30 sites globally
- ZIRCON peer review data published in Lancet Oncology[2]
- Included in EAU guidelines[3] as an emerging technology

Zircaix
(zirconium Zr 89 girentuximab senvedoxam-crdi)

Telix

Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.

1. Intended to remediate a filing issue with the initial Biologics License Application (BLA) submission from June 2024. See Telix ASX disclosures 31 July 2024 and 30 December 2024.
2. Shuch et al. *La*
3. European Asso
4. Albert et al. *Lan*

Indication expansion to grow the opportu

Driving clinical utility and differentiation across the patien



Telix

1. Radioligand therapy.
2. Hepatocellular carcinoma.
3. Androgen deprivation therapy.
4. Prostate-specific antigen.

Current indication

Exp

Sustained leadership in prostate cancer i

PSMA targeting is solved, technology will further unleash

Telix PSMA

Enhan
Proprietary tools a
Telix + SubtlePET, a

Reach access "deserts"
Gozellix® delivers PSMA imaging to the last mile, transforming access



Investment in innovation
Multi-product lifecycle management

New camera technology
Augments sensitivity to enable PSMA detection
low PSA levels[1]. Close cooperation with scanner

Telix

Gozellix brand name subject to final regulatory approval.

1. Hicks et al. *European Urology Open Science*, 2025.
2. Original Equipment Manufacturers.

Total-body Illuccix PET-CT. Patient representative scan - individual results may vary. Credit: BAMF Health.

Zircaix®: “Practice-changing” solution fo

ZIRCON imaging data validates target in ccRCC[1,2]

- **Sensitivity of 86% and specificity of 87%,** PPV[3] of 93% in patients with cT1 indeterminate renal mass (≤7cm)
- **High diagnostic performance** for detection and characterization of small and very small renal masses
- **Primary and secondary endpoints met by** all three readers
- **No safety concerns**
- **Non-invasive technique** may be especially beneficial to those at risk of complications from a surgical renal mass biopsy

TLX250-CDx

“has a favorable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterization of ccRCC, which has the potential to be practice changing[1].”

Telix

Zircaix brand name subject to final regulatory approval.

1. Shuch et al. *Lancet Oncol.* 2024.
2. Telix ASX disclosures 7 November 2022.
3. Positive predictive value.

Pixclara®: Preparation for 2025 commerci

Unmet need for delineating progressive disease from treat

- **U.S. total addressable market:** 95,000+ scans across multiple clinical indications; market value US$475-665M[1]
- **Initial indication:** Characterizing recurrent glioma or treatment-induced change. Patient selection tool for TLX101 therapeutic
- A potentially valuable tool for management of progression/ treatment monitoring
- **Orphan drug designation,** potential to meet major unmet need
- **Widely used in Europe and recommended** in the EANM / EANO / RANO / SNMMI guidelines for PET imaging of gliomas[1]
- **First PET-based response assessment criteria** for diffuse gliomas issued by RANO in January 2024[2]

NDA submitted to FDA in 2024, granted Priority Review and provided a PDUFA goal date of 26 April 2025

ROC[3] a
patients
glioma
demons
accurac
compar



Telix

Pixclara brand name subject to final regulatory approval.

1. Management estimate based on latest incidence (American Cancer Society, ACS data) and pricing models.
2. Verger et al. *EJNMMI*. 2025.
3. Albert et al. *Lancet Oncol*. 2024.
4. Receiver operating characteristic.
5. Veronesi et al. *J Nucl Med*. 2023.


Telix
Manufacturing
Solutions

Global manufacturing capability is key to

Ensuring confidence through world-class manufacturing a

Our strategy is based on:

Harnessing resources and expertise

Scaling to meet rapid growth and demand

Building partnerships to drive success

Telix

Global patient reach

A strategy combining partnerships and owned assets



Telix

RLS acquisition subject to completion.
Expected early Q1 2025.

U.S. coverage

Multiple channels ensure patient access and industry lead

Strategic partner pharmacy network

CardinalHealth
PharmaLogic Take The Lead
UPPI
JUBILANT RADIOPHARMA



Telix-owne

Telix

RLS acquisition subject to completion.
Expected early Q1 2025.

More than “bricks and mortar” – talent an

Global reach, international talent pool and an unrivalled R

Optimal Tracers

California, U.S.

artms

Vancouver, Canada

IsoTherapeutics

Texas, U.S.

Telix

RLS acquisition subject to completion.
Expected early Q1 2025.

Delivering in 2025

Multiple drivers of value creation

Foundations in place for rapid and sustainable growth

2025

A transformative year for Telix

Commercial Growth

- Proven track record of delivery
- Preparing to launch multiple products in 2025[1]
- Ex-U.S. business expansion

Pipeline Developme

- Multiple ne catalysts
- Key therap assets pro to pivotal t
- Advancem next-gener assets

Telix

1. Subject to regulatory approval.

Delivering the plan

Catalysts

Commercial portfolio and geographic expansion

Progress late-stage therapeutic pipeline

Advance radiopha

H1 2025

ProstACT GLOBAL (TLX591) Ph 3 interim readout	ZOLAR (TLX300) patient dosing
TLX592 alpha therapeutic trial commencement	TMS Brussels South GMP[2] accreditation and "hot" doses
IPAX-2 and IPAX-Linz (TLX101) therapy studies readouts	Illuccix Brazil, EU and UK approval decisions
Gozellix[1] & Pixclara[1] FDA approval decisions (U.S.)	Illuccix China Ph 3 bridging study complete
TLX250 program update and interim data	PSMA biopsy expansion study commencement
RLS acquisition completion (expected early Q1 2025)	Novel biologics platform and Tx assets transaction completion

Telix

1. Brand names subject to regulatory approval
2. Good manufacturing practice.

Contact :

Belinda White
Investor Relations
belinda.white@telixpharma.com

Telix